Related Experiment Video
Updated: Feb 14, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case
Jeffrey J Cies, Wayne S Moore1, Adela Enache2
1The Center for Pediatric Pharmacotherapy LLC, Pottstown, PA.
Insights
Ceftaroline pharmacokinetics in critically ill children differ from adults, showing faster clearance and larger volume of distribution. Higher doses may be needed for effective treatment of methicillin-resistant Staphylococcus aureus infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Critical Care Medicine
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in pediatric intensive care units (PICUs).
- Ceftaroline is a key antibiotic for treating MRSA infections, but its pharmacokinetic profile in critically ill children is not well-established.
- Understanding ceftaroline pharmacokinetics is crucial for optimizing treatment and improving patient outcomes.
Purpose of the Study:
- To characterize the pharmacokinetics of ceftaroline in critically ill children with suspected or confirmed MRSA infections.
- To evaluate the microbiological and clinical outcomes of ceftaroline treatment in this population.
- To inform potential adjustments in dosing strategies for pediatric patients.
Main Methods:
- Retrospective review of electronic medical records from a pediatric hospital.
- Analysis of ceftaroline samples for therapeutic drug management in critically ill children.
- Evaluation of microbiological and clinical response in patients with documented MRSA infections.
Main Results:
- Seven pediatric patients received ceftaroline for MRSA infections.
- Pharmacokinetic analysis revealed increased volume of distribution (86%), increased clearance (71%), and shorter half-life (100%) compared to package insert estimates.
- All six evaluable patients (100%) achieved a positive microbiological and clinical response.
Conclusions:
- Ceftaroline pharmacokinetics in critically ill children differ significantly from healthy pediatric and adult populations.
- Faster clearance and larger volume of distribution suggest that current dosing may be insufficient.
- Higher doses or more frequent dosing intervals of ceftaroline may be necessary to achieve optimal therapeutic exposures in PICU patients.
Objectives:
To describe the ceftaroline pharmacokinetics in critically ill children treated for suspected or confirmed methicillin-resistant Staphylococcus aureus infections, including blood stream infection and describe the microbiological and clinical outcomes.
Design:
Retrospective electronic medical record review.
Settings:
Free-standing tertiary/quaternary pediatric children's hospital.
Patients:
Critically ill children receiving ceftaroline monotherapy or combination therapy for suspected or confirmed methicillin-resistant S. aureus infections in the PICU.
Intervention:
None.
Measurements And Main Results:
Seven patients, three females (43%), and four males (57%), accounted for 33 ceftaroline samples for therapeutic drug management. A median of four samples for therapeutic drug management was collected per patient (range, 2-9 samples). The median age was 7 years (range, 1-13 yr) with a median weight of 25.5 kg (range, 12.6-40.1 kg). Six of seven patients (86%) demonstrated an increase in volume of distribution, five of seven patients (71%) demonstrated an increase in clearance, and 100% of patients demonstrated a shorter half-life estimate as compared with the package insert estimate. Six of seven patients (85.7%) had documented methicillin-resistant S. aureus growth from a normally sterile site with five of six (83.3%) having documented BSI, allowing six total patients to be evaluated for the secondary objective of microbiological and clinical response. All six patients achieved a positive microbiological and clinical response for a response rate of 100%.
Conclusions:
These data suggest the pharmacokinetics of ceftaroline in PICU patients is different than healthy pediatric and adult patients, most notably a faster clearance and larger volume of distribution. A higher mg/kg dose and a more frequent dosing interval for ceftaroline may be needed in PICU patients to provide appropriate pharmacodynamic exposures. Larger pharmacokinetic, pharmacodynamic, and interventional treatment trials in the PICU population are warranted.
More Related Videos
Related Concept Videos
Confirmation Biases
Resistors In Series
In a series circuit, the...
Series Resonance
Resistivity
Resistance
Series and Parallel Capacitors
First, consider capacitors connected in series to a battery. In this configuration, the plate connected to the battery's positive terminal develops a positive charge, while the plate attached to the negative terminal becomes negatively charged. An equal magnitude of charge is induced on the...

